Learn about Biomarkers – what they are, why they are important, and what Genzyme is doing to understand Biomarkers in Pompe disease. The event will be hosted by Genzyme and the AMDA, together to support the first Pompe Awareness Day!
Date: Tuesday, April 15, 2014
Time: 3 pm ET
Duration: 60 minutes
Guest speaker:
Alison McVie – Wylie, PhD
Scientific Director of the Biologics Pharmacology and Pharmacokinetics at Genzyme
Register now at https://secure.confertel.net/
ABOUT THE AMDA
The Acid Maltase Deficiency Association was established in 1995 to assist in funding research and to promote public awareness of Pompe disease. Pompe disease is one of a family of 49 rare genetic disorders known as Lysosomal Storage Diseases or LSDs. Pompe disease is also known as Acid Maltase Deficiency or Glycogen Storage Disease type II. It affects an estimated 5,000 to 10,000 people in the developed world.
ABOUT GENZYME, a SANOFI COMPANY
Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world’s leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
We’ve kept our roots in the Boston area: our headquarters, Genzyme Center, is located in Cambridge, Massachusetts, home to venerable universities, teaching hospitals, and a thriving biotechnology community. But we also operate in every other region of the globe.
Stay Connected
Sign up for updates straight to your inbox.